中文摘要：

目的：研究普洱熟茶（发酵）和普洱绿茶（未发酵）这 2 种常见普洱茶的抗 HIV 作用。方法：采用 MTT 比色法检测普洱茶提取物对 C8166, MT4 和 PBMC 细胞的毒性作用; 细胞病变法检测化合物对 HIV-1 急性感染的抑制活性。采用细胞病变法和 HIV-1 p24 抗原 ELISA 方法检测普洱茶提取物的抗 HIV 活性作用; 结果：所有普洱茶提取物都具有较低的细胞毒性 CC50为 120.63 524.95 μg·mL 1。所有普洱茶提取物均能抑制 HIV 诱导细胞形成合胞体其 EC50为 11.13 67.49 μg·mL 1。普洱茶水提物的抑制作用比醇提物的抑制作用要好, 并且普洱熟茶的抑制作用好于普洱生茶, 尤其是 YYP-31, 其 SI 值为 42.40。YYP-31 对HIV-RF和 HIV-2CBL-20也有很好的抑制作用, 其 EC50分别为 30.82 和 39.79 μg·mL 1。YYP-31 还能很好地抑制 HIV-1IIIB急性感染C8166 细胞和 HIV-1KM018感染PBMC细胞p24抗原的产生, 其EC50分别为14.95和 74.63 μg·mL 1。YYP-31能阻止正常细胞C8166与 HIV-1 慢性感染细胞 H9/HIV-1IIIB之间的融合, EC50为 234.27 μg·mL 1。提取物 YYP-31 与 AZT 联合用药具有显著的协同抗HIV 作用,但是对 HIV 逆转录没有抑制作用。结论：普洱茶提取物具有很好的抗 HIV 的活性作用, 可以作为一种 HIV 辅助治疗的产品或保健品用于 HIV 患者的治疗过程中。

英文摘要：

AIM： To evaluate the anti-H1V activities of extracts from two commonly forms of Pu-erh tea （fermented）, green tea-like （unfermented）. METHODS： The cytotoxicities of extracts on C8166, MT4 and PBMC were assessed by MTT and the anti-HIV activities of extracts were evaluated by syncytium reduction and p24 antigen assay. RESULTS： All extracts had low cyto- toxieities with the CC50 from 120.63 to 524.95 μg-mL-1. All extracts can inhibit HIV-induced cytopathic effects, with ECs0 various from 11.13 to 67.49 μg.mL-1. The WEPT＇s were better than EEPTs, moreover the FPT＇s water extracts were better than the GTLPT＇s especially YYP-31 with SI value 42.40. YYP-31 also inhibited HIV-1RF and HIV-2cBL-20 infection with EC50 of 30.82 and 39.79 μg-mL-1, respectively. YYP-31 reduced p24 antigen expression in HIV-1Hm acute infected C8166 and in HIV-1KM018 infected PBMC with EC50 values of 14.95 and 74.63 μg.mL-1, respectively. YYP-31 blocked the fusion between normal C8166 ceils and HIV-1 chronically infected H9 cells with EC50 values of 234.27 μg.mL-1. It exhibits markedly synergistic anti-HIV activity in combination with AZT but can＇t inhibit activities of reverse transcriptase. CONCLUSION： Pu-erh tea extracts exhibit highly efficient anti-HIV-1 activity and can be considered to be used to as a complementary therapy or a health product to HIV patients.